Literature DB >> 17268793

Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor.

Karin Tegerstedt1, Andrea Franzén, Torbjörn Ramqvist, Tina Dalianis.   

Abstract

One immunization with murine polyomavirus (MPyV) VP1 virus-like particles containing a fusion protein between MPyV VP2 and the extra cellular and transmembrane domain of Her2 (Her2(1-683)PyVLPs) efficiently protects BALB/c mice from outgrowth of the Her2 expressing tumor D2F2/E2. To possibly enhance the anti-Her2 immune response and abrogate the induced anti-VLP antibody response, immunization with murine dendritic cells (DCs) loaded with Her2(1-683)PyVLPs was performed. Mice were immunized once or more with 5 or 50 microg Her2(1-683)PyVLPs alone or loaded on DCs, and challenged 14 days after the last immunization with a lethal dose of Her2-positive D2F2/E2 cells. Mice were protected from tumor outgrowth, when immunized only once with 5 or 50 mug Her2(1-683)PyVLPs loaded on DCs, or 50 mug of Her2(1-683)PyVLPs alone, whereas immunization once or more with 5 mug of Her2(1-683)PyVLPs alone only protected half of the mice. Immunization with recombinant Her2 protein alone, or loaded on DCs, did not induce tumor immunity. Using both immunization strategies, Her2-specific T cell immunity was demonstrated, while Her2-specific antibodies were not detected. Loading VLPs on DCs reduced anti-VLP antibodies sixfold, but did not influence the efficiency of subsequent immunizations. Notably, DC maturation by Her2(1-683)PyVLPs in vitro was not demonstrated although the IL-12 production was significantly increased. In conclusion, loading of VLPs on DCs can enhance specific VLP immunization considerably.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17268793     DOI: 10.1007/s00262-007-0281-8

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  9 in total

1.  Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.

Authors:  Sharmila Pejawar-Gaddy; Yogendra Rajawat; Zoe Hilioti; Jia Xue; Daniel F Gaddy; Olivera J Finn; Raphael P Viscidi; Ioannis Bossis
Journal:  Cancer Immunol Immunother       Date:  2010-07-21       Impact factor: 6.968

2.  Dendritic cells transfected with Her2 antigen-encoding RNA replicons cross-prime CD8 T cells and protect mice against tumor challenge.

Authors:  Birgit Edlich; Leah J Hogdal; Barbara Rehermann; Sven-Erik Behrens
Journal:  Vaccine       Date:  2010-09-29       Impact factor: 3.641

3.  CD4+ and CD8+ T cells can act separately in tumour rejection after immunization with murine pneumotropic virus chimeric Her2/neu virus-like particles.

Authors:  Kalle Andreasson; Mathilda Eriksson; Karin Tegerstedt; Torbjörn Ramqvist; Tina Dalianis
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

4.  Murine polyomavirus virus-like particles carrying full-length human PSA protect BALB/c mice from outgrowth of a PSA expressing tumor.

Authors:  Mathilda Eriksson; Kalle Andreasson; Joachim Weidmann; Kajsa Lundberg; Karin Tegerstedt; Tina Dalianis; Torbjörn Ramqvist
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

5.  Leishmania mexicana Gp63 cDNA Using Gene Gun Induced Higher Immunity to L. mexicana Infection Compared to Soluble Leishmania Antigen in BALB/C.

Authors:  H Rezvan; R Rees; Sa Ali
Journal:  Iran J Parasitol       Date:  2011-12       Impact factor: 1.012

6.  Construction of polyomavirus-derived pseudotype virus-like particles displaying a functionally active neutralizing antibody against hepatitis B virus surface antigen.

Authors:  Milda Pleckaityte; Corinna M Bremer; Alma Gedvilaite; Indre Kucinskaite-Kodze; Dieter Glebe; Aurelija Zvirbliene
Journal:  BMC Biotechnol       Date:  2015-09-15       Impact factor: 2.563

Review 7.  Interaction Between Virus-Like Particles (VLPs) and Pattern Recognition Receptors (PRRs) From Dendritic Cells (DCs): Toward Better Engineering of VLPs.

Authors:  Jesús Zepeda-Cervantes; Josué Orlando Ramírez-Jarquín; Luis Vaca
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

8.  Virus like particles as a platform for cancer vaccine development.

Authors:  Hui Kian Ong; Wen Siang Tan; Kok Lian Ho
Journal:  PeerJ       Date:  2017-11-15       Impact factor: 2.984

Review 9.  Emerging Concepts and Technologies in Vaccine Development.

Authors:  Morgan Brisse; Sophia M Vrba; Natalie Kirk; Yuying Liang; Hinh Ly
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.